JPRN-C000000184已完成2 期
Phase II study of gefitinib in untreated advanced non-small cell lung cancer with EGF receptor mutations - Phase II study of gefitinib in untreated advanced non-small cell lung cancer with EGF receptor mutations
Hokkaido Lung Cancer Clinical Study Group0 个研究点目标入组 16 人开始时间: 2005年9月12日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Serious concomitant systemic disorders 2.Uncontrollable angina, acute myocardial infarction or severe heart failure within 3 months 3.Uncontrollable diabetes mellitus or hypertension 4.Active infection 5.Interstitial pneumonia 6.Uncontrollable pleural effusion 7.Active ulcer 8.Active second malignancy 9.History of severe hypersensitivity 10.Severe SVC syndrome 11.Pregnancy 12.Other severe complication
研究者
相似试验
未知
不适用
PhaseII stady of gefitinib and in patients with relapsed advanced non-small cell lung cancerJPRN-C000000142Department of Medical Oncology Kinki University School of Medicine30
已完成
2 期
Phase II study of gefitinib therapy inserted by chemotherapy as first line treatment for advanced non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) mutatioon-small-cell lung cancerJPRN-UMIN000001738Thoracic Medical Oncology, National Cancer Center Hospital33
已完成
不适用
A phase II trial of gefitinib in combination with bevacizumab as first line therapy for advanced non-small-cell lung cancer with mutated EGFRnon-small-cell lung cancerJPRN-UMIN000004296Okayama Lung Cancer Study Group42
已完成
2 期
A phase II study of first-line gefitinib for advanced and recurrent EGFR mutation positivenon-small cell lung cancerwith high-risk factorsnon-small cell lung cancerJPRN-UMIN000004822Kanagawa Cancer Center37
已完成
不适用
A phase II study of gefitinib as first-line treatment for elderly patients with advanced lung adenocarcinoma who have active EGFR mutationslung adenocarcinomaJPRN-UMIN000002783agano lung cancer study meeting15